{"entity":{"id":"nicholas-turner","kind":"person","name":"Nicholas Turner","aka":[],"tldr":"Breast cancer researcher who turned ctDNA into a tool for choosing treatment, leading SERENA-6 and CAPItello-291.","summary":"Nicholas Turner is Professor of Molecular Oncology at The Institute of Cancer Research and a consultant medical oncologist at The Royal Marsden, where he leads the Ralph Lauren Centre for Breast Cancer Research. His specialisms are breast cancer, circulating tumour DNA, endocrine resistance and the CDK4/6 and PI3K pathway. He turned circulating tumour DNA into a tool for choosing treatment through plasmaMATCH, the Lancet Oncology trial of ctDNA analysis to direct therapy in advanced breast cancer, and SERENA-6, which tests camizestrant. He also led the capivasertib programme, with CAPItello-291 reported in the New England Journal of Medicine in hormone receptor-positive advanced breast cancer. His ICR profile and PubMed listing are linked.","asOf":"2026-09-08","links":[{"label":"ICR profile","url":"https://www.icr.ac.uk/research-and-discoveries/our-research/researchers/professor-nicholas-turner"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Turner%20NC%5BAuthor%5D%20breast%20ctDNA"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["liquid-biopsy"],"targets":["estrogen-receptor","akt"],"drugs":["capivasertib","camizestrant"],"companies":[],"institutions":["royal-marsden","icr-london"],"pathways":[],"terms":[],"trials":["capitello-291","serena-6"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Molecular Oncology, ICR; Consultant Medical Oncologist, Royal Marsden","institutionId":"royal-marsden","specialisms":["Breast cancer","Circulating tumour DNA","Endocrine resistance","CDK4/6 and PI3K pathway"],"profiles":[{"label":"ICR profile","url":"https://www.icr.ac.uk/research-and-discoveries/our-research/researchers/professor-nicholas-turner"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Turner%20NC%5BAuthor%5D%20breast%20ctDNA"}],"papers":[{"title":"Capivasertib in hormone receptor-positive advanced breast cancer (CAPItello-291)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2214131"},{"title":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH)","journal":"Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(20)30444-7"}],"orcid":"0000-0001-8937-0873"},"route":"/people/nicholas-turner/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"}],"target":[{"id":"akt","kind":"target","name":"AKT","route":"/targets/akt/"},{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/"}],"drug":[{"id":"camizestrant","kind":"drug","name":"Camizestrant","route":"/drugs/camizestrant/"},{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/"}],"institution":[{"id":"bcrf","kind":"institution","name":"Breast Cancer Research Foundation","route":"/institutions/bcrf/"},{"id":"icr-london","kind":"institution","name":"The Institute of Cancer Research","route":"/institutions/icr-london/"},{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","route":"/institutions/royal-marsden/"}],"trial":[{"id":"capitello-291","kind":"trial","name":"CAPItello-291","route":"/trials/capitello-291/"},{"id":"plasmamatch","kind":"trial","name":"plasmaMATCH","route":"/trials/plasmamatch/"},{"id":"serena-6","kind":"trial","name":"SERENA-6","route":"/trials/serena-6/"}],"paper":[{"id":"paper-garcia-murillas-molecular-relapse-detection-jama-oncol-2019","kind":"paper","name":"Assessment of molecular relapse detection in early-stage breast cancer","route":"/key-papers/paper-garcia-murillas-molecular-relapse-detection-jama-oncol-2019/"},{"id":"paper-garcia-murillas-ctdna-mutation-tracking-stm-2015","kind":"paper","name":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","route":"/key-papers/paper-garcia-murillas-ctdna-mutation-tracking-stm-2015/"},{"id":"paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023","kind":"paper","name":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","route":"/key-papers/paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023/"}],"roadmap":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}]}}